Given that HNSCC has a 5-year survival rate of less than 60%, which has improved little over the last 20 years [16], these studies of the impact of IL-6 on CSCs provide strong motivation for the development of anti-IL-6 therapies for the targeted treatment of HNSCC. This evidence concerns the gene IL6 and head and neck squamous cell carcinoma.